Bromantane (Ladasten; bromantan) is a synthetic stimulant and nootropic of the adamantane chemical class — a bicyclic carbon scaffold related to the diamond crystal lattice structure — combined with an N-phenyl substituted amine. Developed in the Soviet Union in the late 1970s–1980s, bromantane was created to enhance physical and mental performance under extreme conditions (heat, cold, physical exertion) and was used by Soviet military personnel and athletes. It is unique among stimulants in its mechanism: unlike classical stimulants that block or reverse monoamine transporters, bromantane enhances dopamine synthesis — increasing the enzymes that produce dopamine rather than simply preventing its reuptake or causing its release.
Bromantane's pharmacological profile is genuinely atypical within the stimulant class. It combines dopamine synthesis enhancement with serotonin reuptake inhibition and GABAergic anxiolytic activity — a combination that produces wakefulness, mood enhancement, and reduced fatigue without the cardiovascular stimulation, cardiovascular activation, or strong euphoria characteristic of amphetamines or cocaine. Community reports describe it as a subtle but genuine enhancer of energy, mood, and motivation with a particularly clean side effect profile and notably anxiolytic rather than anxiogenic quality — the opposite of most stimulants.
Bromantane gained international notoriety as a sports doping agent: the 1996 Atlanta Olympics produced multiple positive tests among Russian athletes, and the International Olympic Committee subsequently banned it as a performance-enhancing drug. It is approved as a pharmaceutical in Russia under the trade name Ladasten. The compound's unique mechanism — indirect dopamine synthesis enhancement rather than transporter interaction — has attracted scientific interest in the context of Parkinson's disease, depression, and exercise performance.
Safety at a Glance
High Risk- Advantages of Bromantane's Mechanism
- The indirect dopamine synthesis mechanism offers genuine harm reduction advantages:
- Toxicity: Acute Toxicity Bromantane has a favorable acute toxicity profile based on both animal studies and its clinical use in...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid (+3 more)
- Overdose risk: LD50 of bromantane in mice has been established at 8100 mg/kg. It is strongly recommended that on...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 10 hrsHow It Feels
Bromantane is the rarest of psychoactive experiences: one that works by subtraction rather than addition. Within one to two hours of oral ingestion, there is no perceptible shift in consciousness, no onset that can be pointed to and labeled. What happens instead is that the background noise of anxiety and fatigue begins to diminish. It is as though someone has been slowly turning down the volume on two radio stations that had been playing just below conscious awareness, and their absence leaves behind a clarity that feels not enhanced but restored.
At its functional peak, which may take several days of consistent dosing to fully manifest, bromantane produces a state that is difficult to describe precisely because it feels so much like normal functioning at its best. Anxiety is reduced without sedation. Motivation is improved without stimulation. The mind is clear, capable, and curiously unhurried. Tasks are approached with a calm efficiency that lacks the driven quality of stimulants. There is no euphoria, no sense of being enhanced or altered. Instead, there is the quiet satisfaction of a mind that is working the way it is supposed to work, without the friction and noise that typically accompany ordinary consciousness.
The physical effects are nearly invisible. There is no change in heart rate, no appetite suppression, no jaw tension, no sweating. The body feels normal, perhaps marginally more energetic, as though the effort cost of physical activity has been slightly reduced. Some users report improved physical endurance and recovery, though these effects are subtle enough to require attentive self-observation to detect.
The offset of bromantane is as imperceptible as its onset. When discontinued after a period of regular use, there is a gradual return of the baseline anxiety and fatigue that had been quietly managed. This return is not a crash or a withdrawal but simply a regression to the mean. The substance leaves no hangover, no rebound, no deficit. Its overall character is one of such thoroughgoing subtlety that many users question whether it is working at all, until they stop taking it and notice the difference. In a world of psychoactive substances that announce their presence loudly, bromantane is a whisper that you only notice when it stops.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(4)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(3)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
Bromantane's primary mechanism is enhancement of dopamine biosynthesis, achieved by increasing the expression and activity of dopamine biosynthetic enzymes — specifically tyrosine hydroxylase (TH) and DOPA decarboxylase (DDC), the rate-limiting steps in dopamine production from tyrosine. This indirect mechanism produces a more gradual, sustained elevation of dopamine availability compared to releasing agents or reuptake inhibitors.
Additionally, bromantane is an atypical stimulant in that it:
- Inhibits serotonin reuptake (SERT inhibition) — contributing to mood enhancement and reducing anxiety
- Enhances GABAergic transmission — producing anxiolytic effects unique among stimulants; this distinguishes bromantane from virtually all other compounds in the class
- Inhibits norepinephrine reuptake weakly — though the mechanism of norepinephrine elevation is not fully characterized
The combination of dopamine synthesis enhancement + serotonin reuptake inhibition + GABA enhancement produces a pharmacological profile unlike any other common stimulant, explaining its distinctive subjective character.
Receptor Profile
- Dopamine synthesis — Increased TH and DDC expression; sustained dopamine elevation
- SERT — Serotonin reuptake inhibition; mood stabilization, anxiolysis
- GABA-A — Positive modulation; anxiolytic, anti-stress effects
- NET — Mild norepinephrine effects; wakefulness
Pharmacokinetics
Based on clinical pharmacological studies (bromantane has some published clinical data as a Russian pharmaceutical):
- Onset: 1–2 hours oral
- Peak: 2–4 hours
- Duration: 6–12 hours; effects may build over days with repeated dosing due to enzyme induction mechanism
- Bioavailability: High; lipophilic adamantane scaffold facilitates oral absorption and CNS penetration
Adaptogenic Properties
Bromantane is classified as an actoprotector — a category of performance-enhancing substances developed in Soviet pharmacology that enhance physical and mental performance under stress without the side effect profiles of classical stimulants. This category emphasizes performance under adverse conditions (heat, cold, hypoxia) rather than simply euphoria or wakefulness.
Detection Methods
Urine Detection
Bromantane (Ladasten) is an adamantane derivative with combined anxiolytic and stimulant properties. Its unique adamantane-bromine structure is not related to amphetamines and does not cross-react with standard immunoassays. The urine detection window is approximately 3 to 7 days, reflecting the compound's lipophilicity and tissue accumulation. Metabolites include hydroxylated adamantane derivatives and debrominated products.
Blood and Serum Detection
Blood detection windows for bromantane are approximately 12 to 48 hours. The compound's lipophilicity contributes to relatively high volume of distribution and extended clearance. LC-MS/MS is the preferred analytical method.
Standard Drug Panel Inclusion
Bromantane is NOT included on standard drug panels. It is on the WADA prohibited substance list (category S6: stimulants), and anti-doping laboratories have validated methods for its detection. Routine workplace or clinical drug testing does not detect bromantane.
Confirmatory Methods
GC-MS and LC-MS/MS with reference standards identify bromantane. The bromine atom produces a characteristic isotope pattern. Anti-doping laboratories routinely include bromantane in their screening panels.
Reagent Testing (Harm Reduction)
Limited reagent testing data exists for bromantane. The Marquis reagent is expected to show no reaction due to the adamantane structure. Reagent testing has very limited utility for this compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| MAOI | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Myristicin | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,4-Butanediol | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 1B-LSD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1cP-AL-LAD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1cP-LSD | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
History
Soviet Development
Bromantane was developed in the USSR in the late 1970s and early 1980s at the Institute of Pharmacology of the Russian Academy of Medical Sciences, led by Sergei Barchukov. It was developed specifically as an "actoprotector" — a category of pharmacological agents designed to enhance physical and cognitive performance under extreme conditions (heat, cold, radiation, hypoxia, physical exhaustion) without the side effects of classical stimulants. The adamantane scaffold was of particular interest in Soviet pharmacology for its lipophilicity, metabolic stability, and CNS penetrance.
Military and Sports Use
Bromantane was used by Soviet military personnel in conditions of extreme physical stress and by Soviet athletes. Its anti-fatigue and performance-enhancing properties made it valuable in both contexts. The collapse of the Soviet Union did not end its use in Russian sports pharmacology — it continued to be used by athletes representing the Russian Federation.
1996 Atlanta Olympics Doping Scandal
The 1996 Summer Olympics in Atlanta produced a significant doping controversy when multiple Russian athletes — including swimmers and track athletes — tested positive for bromantane. The IOC initially struggled to classify it because it was not on the standard prohibited list; it was eventually banned under the anti-doping framework as a "masking agent" (it was alleged to potentially mask the use of other stimulants) and performance enhancer. This episode brought bromantane international attention.
Russian Pharmaceutical Approval
Bromantane received Russian pharmaceutical approval (as Ladasten) for use in asthenic conditions — states of fatigue, reduced motivation, and cognitive decline — and has been used in Russian clinical practice with an established, if not Western-validated, clinical record. This provides a meaningful safety dataset absent for most research chemicals.
Contemporary Interest
Bromantane has attracted renewed interest in Western nootropic and cognitive enhancement communities, partly driven by the appeal of its unusual mechanism (dopamine synthesis enhancement) and its relatively benign clinical record from Russian use. It represents one of a class of Soviet-era pharmacological agents — alongside semax, selank, and others — that have entered Western nootropic markets with the benefit of decades of use in Russian clinical practice.
Harm Reduction
Advantages of Bromantane's Mechanism
The indirect dopamine synthesis mechanism offers genuine harm reduction advantages:
- Lower acute cardiovascular activation than releasing agents or reuptake inhibitors
- GABAergic anxiolytic component reduces anxiety risk (opposite of most stimulants)
- Gradual onset with enzyme induction means lower risk of acute overdose profile compared to rapid-onset stimulants
Dose Reference
Based on Russian clinical data and community reports:
- Clinical therapeutic range: 50–100 mg daily (Russian pharmaceutical dosing)
- Nootropic community range: 25–100 mg oral
- Duration: Effects may build over days-to-weeks with regular use as enzyme expression increases
Allow for Onset Delay
Bromantane's mechanism (enzyme induction) means full effects may require days of regular dosing rather than occurring immediately on day 1. Users who expect immediate effects may over-escalate dose before the compound's full effect is established.
Not a Party Drug
The anxiolytic, gradual, mood-stabilizing profile is not suited for recreational use in social or party settings. It is best used as a productivity and performance enhancer with consistent daily use.
Drug Interactions
- MAOIs — Elevated dopamine synthesis + MAOI-mediated reuptake inhibition could produce excessive dopaminergic stimulation; caution
- Dopamine agonists (levodopa, etc.) — Additive dopaminergic effects
- Antidepressants — Serotonin reuptake inhibition component warrants caution with serotonergic drugs
No Strong Contraindications Established
Unlike most stimulants, bromantane lacks strong established contraindications based on acute cardiovascular risk. However, given the limited Western clinical data, users with serious medical conditions should consult a healthcare provider.
Toxicity & Safety
Acute Toxicity
Bromantane has a favorable acute toxicity profile based on both animal studies and its clinical use in Russia. The LD50 in animals is high relative to effective doses, and clinical use has not produced significant rates of serious adverse events at therapeutic doses.
Cardiovascular Profile
A distinctive feature of bromantane's toxicity profile is its limited cardiovascular stimulation compared to classical stimulants. The indirect dopamine synthesis mechanism does not produce the acute catecholamine surges responsible for tachycardia and hypertension with amphetamines or cocaine. At therapeutic doses, cardiovascular effects are minimal.
Addiction and Dependence Potential
This is an area of genuine uncertainty. Animal studies on bromantane have been inconsistent regarding conditioned place preference (a proxy for addiction potential). Some studies show little to no place preference, consistent with the indirect dopamine synthesis mechanism; others suggest mild preference under certain conditions. Clinical experience in Russia does not report significant addiction, but the compound is used in controlled therapeutic contexts.
Reddit Context
The Reddit post comparing mildronate/meldonium experience with "serious doubts about safety" reflects the broader community questioning of Soviet-developed performance-enhancing drugs. Mildronate (meldonium) — another Soviet-developed performance enhancer — received significant scrutiny following Maria Sharapova's 2016 doping ban. Bromantane exists in a similar context of Soviet-era sports pharmacology with limited Western clinical validation.
Long-Term Safety
Bromantane has been used therapeutically in Russia for decades, providing some long-term safety data — a significant advantage over most research chemicals. However, Western regulatory review and large-scale randomized trials are limited.
Overdose Information
LD50 of bromantane in mice has been established at 8100 mg/kg.
It is strongly recommended that one use harm reduction practices when using this substance.
Unlike other stimulants, bromantane does not seem to produce tolerance, addiction, or withdrawal symptoms upon discontinuation. Due to its irregular mechanism of action, it does not exhibit cross-tolerance with other typical stimulants, and anecdotal reports have claimed it can be used to reduce stimulant tolerance, which is caused in part by downregulation of tyrosine hydroxylase which bromantane can increase.
- Long term effects
Bromantane has been shown to uniquely cause long-term changes to gene expression involved in dopamine metabolism in rats. It is unclear if this effect is relevant to humans.
There are multiple anecdotal reports of long-term increases in energy levels, likely from elevated dopamine, from use of bromantane for periods of several months. These effects are claimed to persist even after stopping use of the drug, although have been noted to diminish over time, on a scale of weeks to a month. In a study investigating bromantane in the treatment of neurasthenia, a persistent reduction in fatigue was noted for a month following withdrawal of the drug.
- Dangerous Interractions
Due to its mechanism of action, bromantane can cause an unexpectedly strong reaction when mixed with other stimulants such as amphetamine, cocaine and/or methylphenidate. It is advised to avoid the use of stimulants with bromantane due to the potential for much stronger reactions than one would expect.
- Germany: Bromantane is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). According to §2 AMG (Medicines Act) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | Minimal with standard use |
| Half | 3 - 5 days |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
Germany: Bromantane is not a controlled substance under the BtMG (Narcotics Act) or the NpSG (New Psychoactive Substances Act). According to §2 AMG (Medicines Act) it would fall under the definition of a medicine because it induces pharmacological effect. By a decision of the European Court of Justice, this definition was declared ineffective because it was not compatible with EU law. Bromantane can be considered legal.
Russia: In Russia Bromantane has been discontinued in 2017 and will not be available in the nearest future.
Switzerland: Bromantane is not controlled under Buchstabe A, B, C and D. It could be considered legal.
United States: Bromantane is uncontrolled in the United States and has not been approved by the FDA for human use. However, this has led nootropic vendor websites to sell bromantane under the label of "not for human consumption."
Responsible use
Tianeptine
Nootropics
Bromantane (Wikipedia)
Bromantane (Isomer Design)
Reichlin, S. (1969). Handbook of Experimental Pharmacology. The American Journal of The Medical Sciences (Vol. 258). https://doi.org/10.1097/00000441-196911000-00008
Krapivin, S. V, Sergeeva, S. A., & Morozov, I. S. (1993). [A quantitative pharmaco-electroencephalographic analysis of the action of bromantane]. Biulleten’ Eksperimental’noi Biologii I Meditsiny, 116(11), 515–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8312546
Burnat, P., Payen, A., Brumant-Payen, C. Le, Hugon, M., & Ceppa, F. (1997). Bromontan, a new doping agent. The Lancet, 350(9082), 963–964. https://doi.org/10.1016/S0140-6736(05)63310-7
Viatleva, O. A., Barchukov, V. G., Morozov, I. S., Salenko, I. A., & Zhirnov, E. N. (2000). [The neuro- and psychophysiological effects of bromantane]. Voenno-Meditsinskii Zhurnal, 321(8), 61–5, 96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10998997
Iezhitsa, I. N., Spasov, A. A., & Bugaeva, L. I. (2001). Effects of bromantan on offspring maturation and development of reflexes. Neurotoxicology and Teratology, 23(2), 213–222. https://doi.org/10.1016/S0892-0362(01)00119-2
Iezhitsa, I. N., Spasov, A. A., Bugaeva, L. I., & Morozov, I. S. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine, 133(4), 380–383. https://doi.org/10.1023/A:1016206306875
Oliynyk, S., & Oh, S. (2012). The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance. Biomolecules and Therapeutics, 20(5), 446–456. https://doi.org/10.4062/biomolther.2012.20.5.446
Morozov, I. S., Klimova, N. V, Karpova, T. D., & Shestopalov, S. S. (n.d.). [The characteristics of the neuropsychotropic activity of bromantane in laboratory animals]. Eksperimental’naia I Klinicheskaia Farmakologiia, 62(2), 3–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10340117
Kudrin, V. S., Sergeeva, S. A., Krasnykh, L. M., Miroshnichenko, I. I., Grekhova, T. V, & Gaĭnetdinov, R. R. (n.d.). [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. Eksperimental’naia I Klinicheskaia Farmakologiia, 58(4), 8–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7580761
Experience Reports (1)
Tips (8)
Monitor your heart rate and blood pressure when using Bromantane. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
Keep a journal when starting Bromantane to track cognitive effects, mood, sleep quality, and side effects. Nootropic effects are often subtle, and subjective tracking helps determine if a substance is genuinely beneficial for you.
Bromantane upregulates tyrosine hydroxylase, which means it actually increases your baseline dopamine production capacity over time rather than depleting it like amphetamines. This is why many report lasting benefits even after discontinuation.
Stay hydrated while using Bromantane. Stimulants increase heart rate and body temperature while suppressing thirst signals. Sip water regularly, roughly 250-500ml per hour, more if dancing or in hot environments.
Sublingual bromantane at 50mg provides noticeable focus within 1-2 hours. The effects are subtle compared to traditional stimulants. Think of it as removing brain fog rather than adding stimulation. Effects build over days of consistent use.
Start low with Bromantane and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Community Discussions (2)
See Also
References (4)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- PubChem: Bromantane
PubChem compound page for Bromantane (CID: 4660557)
pubchem - Bromantane - TripSit Factsheet
TripSit factsheet for Bromantane
tripsit - Bromantane - Wikipedia
Wikipedia article on Bromantane
wikipedia